SEROLOGICAL TUMOR MARKERS - THEIR ROLE.
作者信息
Chander Yogesh, Subramanya H
机构信息
Reader in Microbiology, Armed Forces Medical College, Pune 411 040.
Associate Professor in Pathology, Armed Forces Medical College, Pune 411 040.
出版信息
Med J Armed Forces India. 2000 Oct;56(4):279-281. doi: 10.1016/S0377-1237(17)30207-1. Epub 2017 Jun 12.
Abstract
摘要
相似文献
1
SEROLOGICAL TUMOR MARKERS - THEIR ROLE.
Med J Armed Forces India. 2000 Oct;56(4):279-281. doi: 10.1016/S0377-1237(17)30207-1. Epub 2017 Jun 12.
2
The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors.
Exp Hematol Oncol. 2015 Nov 10;4:32. doi: 10.1186/s40164-015-0027-9. eCollection 2015.
3
Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot study.
Oncol Lett. 2014 Sep;8(3):1112-1118. doi: 10.3892/ol.2014.2312. Epub 2014 Jul 4.
4
Serological and immunohistochemical biomarkers for discrimination between benign and malignant ovarian tumors.
Rom J Morphol Embryol. 2019;60(4):1163-1174.
5
Serological markers of cancer and their applications in clinical trials.
Cancer Res. 1994 Apr 1;54(7 Suppl):2011s-2014s.
6
Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation.
PLoS One. 2010 Nov 15;5(11):e15533. doi: 10.1371/journal.pone.0015533.
7
Prevalence of serological markers and nucleic acid for blood-borne viral infections in blood donors in Al-Baha, Saudi Arabia.
J Infect Dev Ctries. 2016 Jun 30;10(6):619-25. doi: 10.3855/jidc.6666.
8
Serological tumor markers for small cell lung cancer and their therapeutic implications.
APMIS. 1994 Aug;102(8):561-80. doi: 10.1111/j.1699-0463.1994.tb05206.x.
9
Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.
Inflamm Bowel Dis. 2013 May;19(6):1139-48. doi: 10.1097/MIB.0b013e318280b19e.
10
Old and new serological biomarkers in melanoma: where we are in 2009.
Melanoma Res. 2010 Apr;20(2):67-76. doi: 10.1097/CMR.0b013e328335a8c1.
引用本文的文献
1
Title of the article: diagnostic markers for odontogenic tumors: an insight: a review.
Discov Oncol. 2024 Oct 15;15(1):558. doi: 10.1007/s12672-024-01237-0.
2
Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations.
Int J Mol Sci. 2022 Nov 29;23(23):14939. doi: 10.3390/ijms232314939.
3
Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.
Int J Mol Sci. 2018 Aug 24;19(9):2514. doi: 10.3390/ijms19092514.
本文引用的文献
1
CORRELATIONSHIP OF HORMONE RECEPTOR STATUS, p53 MUTATION AND c-erb B-2 OVEREXPRESSION WITH NUCLEAR GRADING IN BREAST CANCERS.
Med J Armed Forces India. 2000 Oct;56(4):305-308. doi: 10.1016/S0377-1237(17)30215-0. Epub 2017 Jun 12.
2
DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.
J Exp Med. 1965 Mar 1;121(3):439-62. doi: 10.1084/jem.121.3.439.
3
Production of embryonal alpha-globulin by transplantable mouse hepatomas.
Transplantation. 1963 Apr;1:174-80. doi: 10.1097/00007890-196301020-00004.
4
BRCA1 mutation testing: controversies and challenges.
Clin Chem. 1997 Jan;43(1):6-8.
5
Hereditary cancer, oncogenes, and antioncogenes.
Cancer Res. 1985 Apr;45(4):1437-43.
6
Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.
Science. 1992 Apr 3;256(5053):102-5. doi: 10.1126/science.1566048.
Zotero 插件